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Abstract: Patients with rheumatic conditions often suffer from related chronic pain. When first-line traditional medications such as 
acetaminophen and anti-inflammatory medications do not suffice, then other options are needed. The traditional medications may 
 ultimately not provide sufficient pain relief, or alternatively, they can pose as a contraindication due to underlying hypertension, renal, 
and/or hepatic disease. Therefore, narcotics are an alluring alternative, which if used in a multidisciplinary and systematic approach to 
the patient, can prove to be quite beneficial in the lives of these patients.
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Introduction
The management of chronic pain is a challenge for 
physicians, who, in the best interest of their patients, 
desire to minimize side effects from pain  relieving 
medications and who, in the name of humanity, 
concurrently seek to provide as much pain relief as 
 possible. Other than prescribing lifestyle changes, 
such as weight loss, physical therapy, yoga, medi-
tation, and exercise, doctors have a limited arsenal 
with which to address chronic pain. Such nonphar-
macologic and self-management approaches to pain 
are indeed important complementary modalities, 
which can help amplify therapeutic effects of phar-
macologic aids. Acetaminophen and nonsteroidal 
anti- inflammatory drugs (NSAIDs) are commonly 
invoked as first-line medications in treating musculo-
skeletal pain. However, when these are ineffective or 
cause adverse side effects or otherwise become con-
traindicated, then opioid analgesics may be beneficial 
alternatives.1 Indeed, there are now official guidelines 
available from professional societies, (such as the 
American Pain Society), regarding incorporation of 
opioids in the management of patients with chronic 
noncancer pain.2
Among the driving forces behind a renewed inter-
est in opioids for the management of muscluloskel-
etal pain are the many potential adverse effects of 
NSAIDs. For example, conditions typically afflicting 
older patients such as osteoarthritis and back pain are 
often treated with NSAIDs. But for many reasons, this 
same population may be especially prone to potential 
adverse effects on blood pressure, renal function, the 
gastrointestinal tract, and the cardiovascular system.3 
For example, one recent Cochrane review concluded 
that NSAIDs should be used cautiously in patients 
with chronic inflammatory arthritis who have a his-
tory of gastrointestinal comorbidity.4 Interestingly, 
topical NSAIDs have been shown to play a more 
benign role, compared with their orally administered 
counterparts. The topical route leads to less systemic 
concentration of the drug and, hence, to a reduction 
in potential side effects.5 However, a meta-analysis of 
the efficacy of topical nonsteroidal anti-inflammatory 
drugs in osteoarthritis observed that topical NSAIDs 
were superior to placebo in the first 2 weeks of 
treatment but not the following 2 weeks (albeit less 
effective than oral NSAIDs).6 Therefore, given the 
observed short duration of pain relief and reduced 
potency, alternative therapies are often sought when 
treating long-term pain.
Anticonvulsants and antiepileptics are alterna-
tive agents sometimes employed for the treatment of 
chronic pain.7 Although these drugs may have less 
adverse impact on renal and gastric function, they 
carry an increased risk of neurological side effects as 
well as potential arrhythmogenic properties. Clearly, 
there exists a significant need for alternative modali-
ties for the management of chronic noncancer pain.8 
This review will revisit the use and side effects of 
opiates for rheumatological conditions. It will not, 
however, address nonstandard interventions such as 
cannabinoids, which have been reviewed elsewhere.
Justification
Opioids have an established role in the therapeutic 
armamentarium for rheumatic diseases. Primarily, 
they are employed for short-term use or as tempo-
rizing therapy until definitive surgical intervention is 
achieved.9 Recently, longer term use of these agents is 
gaining support in chronic degenerative conditions.10 
Properly used, opiates may improve function. For 
example, walking speed may improve in patients tak-
ing opiates for osteoarthritis of the knee.11  Admittedly, 
in a systematic review by Papalionteous et al,12 a small 
negative effect of opiates on cognitive function was 
noted. However, the authors cannot translate the clin-
ical significance of such a finding, and acknowledge 
that this appears contradictory to other papers in their 
review, which found no such effect.
Furthermore, The American Geriatric Society has 
extensively reviewed opioid use in elderly. Their 
guidelines advise physicians to clearly consider opi-
oids if patients still have daily physical limitations, 
moderate to severe pain, or pain-related suboptimal 
quality of life, and who have failed acetaminophen 
use.13 This notion is further supported as per the World 
Health Organization recommendations.
Barriers to the Use of Opioids
The causes of underutilization of opiates by physicians 
in the treatment of noncancer pain are myriad, includ-
ing common fears of addiction, respiratory depression, 
and pharmacological tolerance.11 However, the actual 
risk of addiction seems to be fairly small: 3% to 18% 
in various reports, with an average approximate risk 
of 10% in those on chronic opiate therapy. In a focus 
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group of physicians who expressed their apprehen-
sions regarding opiod therapy in elderly, a fear of 
causing harm was the most commonly cited reason. 
Pain subjectivity and exaggeration of the amount 
of pain was also a common concern.  Interestingly, 
patient-perceived barriers included a reluctance to try 
opiates secondary to concern for costs, side effects, 
potential for addiction, as well as stigma in society 
associated with narcotic use.14
A meta-analysis assessing psychotropic 
 medications and the risk of fracture showed that 
regarding opioid medications, there exists a moderate 
but significant increase in the risk (38%) of fractures.15 
This finding, along with the known risk of increased 
falls in the elderly, such as falls that may arise purely 
from  progressive cognitive decline, is another well-
 established barrier to prescribing narcotics for the 
elderly. Perhaps periodic and consistent cognitive 
assessment schedules should be implemented for 
patients on long-term opioids. This can potentially 
identify and rectify new or rapid declines before they 
result in an incident.
Opioid-induced hyperalgesia (OIH) is another 
potential concern in which the patient’s perception 
of pain worsens due to long-standing opioid use. 
The mechanism for this event is not entirely lucid, 
but a popular theory involves an accumulation of 
 inactive opioid metabolites competitively  obstructing 
the analgesic effects of the active metabolites on 
µ receptors. Another hypothesis behind the amplifica-
tion of pain has to do with activation of the descend-
ing pain pathways (rostral ventromedial medulla) via 
enhanced concentration of neurotransmitters such as 
cholecystokinin and N-methyl-D-aspartate.16 As a 
result of activation of these descending tracts, there 
is increased sensitivity to pain. Although it is diffi-
cult to tease apart opioid tolerance from OIH, there 
are some differences. For example, with tolerance, 
the location and nature of the pain remains the same. 
However, in OIH, the pain takes on a more general-
ized form, as opposed to more focal, and the inten-
sity may be worse than the initial pain symptoms. 
Overall, in OIH, the patient is sensitive to even minor 
painful phenomenon, and the patient’s threshold for 
pain decreases. Furthermore, other generalized neu-
roexcitatory symptoms, including agitation, seizures, 
and even delirium have been reported.16 It is impor-
tant to note that this is a relatively rare occurrence and 
that often an appropriate multidisciplinary approach 
to the patient prevents such a side effect.
Finally, it should be emphasized that research on 
therapeutic effectiveness of various agents in general 
requires valid and reliable measures of pain. Since 
subjective assessments are a barrier to evaluating 
the efficacy of various pain management modalities, 
researchers commonly supplement pain assessments 
with functional assessments.
Opioids and Functional Assessment
Tens of millions of patients are affected by some form 
of arthritis. Although various modalities of treatment 
do exist, objective assessment tools for evaluation 
of the efficacy of specific modalities remain crude.11 
Recently, a gait-related marker has been  investigated 
as a potential objective assessment tool. This is 
because normal ambulatory mechanics are altered 
when patients experience pain from knee osteoarthri-
tis (OA). A common gait adjustment in response to 
pain is a reduction in the speed of walking. In one 
study, Boyer et al11 evaluated ambulatory mechan-
ics in knee OA patients who were on NSAIDs versus 
those on opioids. Overall, both groups demonstrated 
improved walking speeds, suggesting  noninferiority 
of opioids in this situation despite their lack of 
anti-inflammatory benefit. Although the NSAID 
group manifested significant improvement in knee 
joint mechanics, in patients with contraindications 
to NSAID use (that is, recent gastrointestinal bleed-
ing, renal failure, heart failure, etc.), opiates provide 
a plausible alternative therapy.17
nociceptive effects of Opioids
Opioid-induced hyperalgesia (OIH) has been described 
as increased sensitivity to stimuli that normally pro-
voke pain or exacerbation of pain in the absence of 
new tissue damage.18 OIH has been seen to develop 
after prolonged exposure to opioids and is defined as 
a state of nociceptive sensitization.19 Although it has 
been described in medical literature since 1800, the 
incidence is still unknown and the diagnosis remains 
difficult to secure. Clinically, OIH manifests as hyper-
esthesia or allodynia and may be accompanied by other 
signs of opioid toxicity (eg, myoclonus,  delirium, 
and seizures). Commonly, patients report worsening 
pain despite  increasing doses. Typically, the worsen-
ing pain cannot be explained by  progression of the 
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original condition.20 Morphine is the most common 
offending agent.21 The precise molecular mechanism 
of OIH, while not yet understood, is generally thought 
to result from neuroplastic changes in the peripheral 
and central nervous system (CNS) that lead to sen-
sitization of pronociceptive pathways. While there 
are many proposed mechanisms, those involving 
the central glutaminergic system, spinal dynorphins, 
descending facilitation, and genetics have been 
highlighted. Of these, the central glutaminergic sys-
tem is considered the most likely possibility. Other 
hypotheses invoke N-methyl-D-aspartate (NMDA) 
receptors, inhibition of the glutamate transporter sys-
tem, facilitation of calcium-regulated intracellular 
protein kinase C, and cross talk of neural mechanisms 
of pain and tolerance.19
It is also possible that lack of effectiveness with 
opioids may be more common than anticipated. 
 Traditional interventions for OIH include opioid rota-
tion, reduction of the administered dose,  detoxification, 
and use of nonopioid and adjuvant analgesics.19,21 As 
previously noted, a major dilemma resides in distin-
guishing OIH from tolerance. In addition, the clini-
cian must be able to distinguish aggravating factors 
to OIH including progression of the original disease 
process, new interval injury, and clinical exacerbation 
of preexisting pain.19
non-nociceptive effects of Opioids
There may be non-nociceptive effects of opioids on 
the immune system as well.22 Opioids interact with 
3 known receptors: µ, δ, and κ, which are G-protein 
coupled.1 The class of opioids include alkaloids, 
synthetic formulations, and endogenous compounds, 
which occur naturally within the body. Opioids 
function to decrease intracellular calcium levels, 
ultimately resulting in reduction in presynaptic neu-
rotransmitter release. Other than analgesic effects, 
opioids have been found to exert immunosuppres-
sive effects, speculated to be caused by their molec-
ular structure. CNS-mediated immunosuppressive 
effects are related to decreased natural killer cell 
activity along with decreased lymphocyte prolifera-
tion and interferon gamma secretion. Interestingly, 
opioids that do not have the capability to cross the 
blood-brain barrier do not exert such immunosup-
pressive effects.23 The mechanisms with which opi-
oids exert their central effects, (ie, neuroendocrine 
axis via sympathetic nervous system route), remain 
unclear.23,24 There are also reports of peripheral 
immunomodulating effects of opioids, but this is 
a less potent effect as compared with the centrally 
mediated pathway.23 For instance, it has been shown 
that bone marrow cells exposed to chronic opioid 
therapy diminish the ability for macrophage progeni-
tor cells to proliferate upon exposure to macrophage-
colony stimulating factor. Furthermore, phagocytic 
capabilities of macrophages are compromised as a 
result of chronic opioids exposure. Multiple other 
inhibitory effects on NK cells, T cells, and inflam-
matory mediators as a result of opioid exposure, 
have been described.23
So, how does this translate into clinical risk of 
infection and sepsis in patients who are subjected to 
opioid therapy? The answer is not well-established as 
there is only a minimal number of outcome studies. 
However, it is of paramount importance to note that 
pain itself can activate sympathetic systems, thereby 
contributing to hemodynamic instability in the criti-
cally ill patient. Therefore, adequate analgesia is a 
key focus in these patients.23 Furthermore, in rheu-
matologic conditions such as rheumatoid arthritis, for 
example, where an overactive immune system is con-
tributing to pain, patients perhaps may benefit from 
the reported immunosuppressive effects of such opi-
ate therapy.
All opioids are not created equal, meaning some 
exert more immunosuppressive effects than others.23,24 
Based on the results of animal studies, it is known 
that morphine, methadone, codeine, and remifentanyl 
tend to be more immunosuppressive than buprenor-
phine, oxycodone, hydromorphone, and tramadol.24 
Of interest, however, is an observation that tolerance 
may develop against immunosuppressive effects of 
opioids, over time.24 This is an area for further scien-
tific exploration.
Specific Modalities
Weak oral opioids such as tramadol may be effective 
in the management of chronic pain, but the scientific 
evidence for their superiority relative to NSAIDs is 
by and large lacking.25 This is as true for the pain 
related to rheumatoid arthritis as it is to pain related 
to osteoarthritis.25 However, the combination therapy 
of tramadol-paracetamol does appear to be effective 
in chronic low back pain.26
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Indeed, novel combination therapies with opioids, 
both weak and strong, while popular, in general have 
as yet to demonstrate improved function.27
Transdermal delivery systems for opiates are widely 
used. Some such agents may have a role to play in 
the management of osteoarthritis pain.28 Recent stud-
ies with long-acting transdermal buprenorphine have 
suggested an improved quality of life in addition to 
pain relief in elderly patients (mean age 72.8 years) 
with chronic pain.29
Iontophoresis is another drug delivery modal-
ity whereby medications are transdermally carried 
into the skin by an electrical current.30 It has been 
shown that if the current carries the same charge 
as the drug of interest, then this helps to carry the 
drug deep and deposit it in subcutaneous tissues.30 
 Fentanyl has been the most studied opioid for ion-
tophoresis and has been shown to reach steady state 
fairly quickly.30 Another advantage is that its deliv-
ery rate can be varied accordingly.30 Therefore, this 
can be of significant benefit to patients with chronic 
pain syndromes.
It should be noted here that in addition to the 
expected opiate side effects, adverse cutaneous reac-
tions to these delivery systems are common.31
Opioids administered intraarticularly have been 
studied. Some reports show intraarticular opioids 
to be ineffective; others report a significant posi-
tive effect on postoperative analgesia. It may be 
that since the degree of postoperative pain varies 
from patient to patient, a concerted effort must be 
undertaken in order to find the optimal therapeu-
tic regimen. Although many clinical studies have 
been published on the intraarticular administra-
tion of various agents, morphine is the most com-
monly used analgesic after major surgery.32 And 
although its half life is about 2 hours, when intro-
duced intraarticularly, its analgesic effects may last 
24 hours.
Another agent, methadone, is a synthetic long-
acting anesthetic agent with high activity on opi-
oid receptors and a half-life of about 35 hours. It is 
highly bound to plasma protein. After intra-articular 
injection of methadone, analgesic effects last for 
24 hours. Pethidine is an anesthetic opioid drug 
whose half-life is about 4 hours. It has lower affin-
ity to proteins and higher risk of convulsions than 
 morphine. After intraarticular injection of pethidine, 
the duration of anesthetic effect lasts about 12 hours.33 
Tramadol is a weak (selective l receptor) opioid 
agonist. An  intraarticular admixture of tramadol 
with bupivacaine provides a pronounced prolonga-
tion  postoperative analgesia in patients undergo-
ing arthroscopic knee surgery.34 Some studies have 
demonstrated that the  intraarticular injection of 
bupivacain/ fentanyl is also effective, especially so in 
the presence of  synovitis.35 Finally, some researchers 
have suggested that intraarticular administration of 
sufentanil alone or in combination with methylpred-
nisolone after knee meniscectomy is effective, reli-
able, and well tolerated.32
In summary, although a systematic review by 
Gupta et al concluded that when compared with pla-
cebo, intraarticular morphine does provide analgesic 
effects,36 there exists wide variability both between 
and within studies regarding the intensity of analge-
sic properties.36 Hence, it is difficult to extrapolate a 
dose-dependent analgesic effect. Therefore, creating 
dosing guidelines remains challenging.36
Other novel administration routes
The intranasal route of administration seems to be 
promising in multiple situations. For example, it can 
be ideal in the preoperative setting as well as for pain 
control in the postoperative time period.30 It can be 
useful in the pediatric population (eg, in the setting of 
the emergency room) after trauma.30 In this situation, 
the intranasal form works as well as the intramuscu-
lar form and is more acceptable to parents and their 
children.30
conclusions
Overall, there are a wide variety of pain-reliev-
ing modalities in the toolbox of rheumatologists, 
although these agents fall within several broad cat-
egories: anti-inflammatories, acetaminophen-based 
agents, narcotics, numbing anesthetics, and newer 
experimental agents. Each category has its pluses 
and minuses. In the setting of addressing the needs 
of rheumatologic patients, recognizing each patient’s 
unique requirements is key. In the setting of cardio-
vascular, gastrointestinal, or renal disease, low dose 
opiate therapy is well justified, and has been shown 
to be efficacious, even in the older patient. With 
proper counseling, a multidisciplinary approach, 
and frequent follow-up evaluations, opiates may be 
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a viable option in the patient with musculoskeletal 
pain.
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